Small Biotech Innovation Act
- Bill Number
- S. 1930
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-03: Read twice and referred to the Committee on Finance.
- Last Updated
- 2025-12-05T22:50:19Z
AI-Generated Summary
Purpose
The Small Biotech Innovation Act (S. 1930) aims to encourage research and development (R&D) in small biotechnology companies by exempting their drugs from Medicare's drug price negotiation program. This program, established under the Inflation Reduction Act, allows the government to negotiate lower prices for certain high-cost drugs covered by Medicare. The bill creates a narrow exception for qualifying small biotech firms to protect their ability to innovate without facing these price controls.
Key Provisions
- Exception for Qualifying Drugs: Starting in 2029, certain single-source drugs (drugs with no generic or biosimilar competition) from "research and development-intensive small biotech manufacturers" are excluded from being "negotiation eligible drugs" under Medicare's program.
- Definitions:
- Small Biotech Manufacturer: A company with 5 or fewer qualifying single-source drugs that is not owned, controlled, or directed by a foreign government or organized under the laws of a "covered nation" (as defined in U.S. defense laws, generally referring to countries like China or Russia that pose national security risks).
- Research and Development-Intensive: A small biotech manufacturer that spends at least a specified percentage of its average net revenue from the prior three years on R&D, based on standard accounting rules. The required percentage increases with the number of drugs:
- 30% for 1 drug
- 40% for 2 drugs
- 50% for 3 drugs
- 60% for 4 drugs
- 70% for 5 drugs
- Acquisition Rule: If a qualifying manufacturer is bought after 2029 by a larger company that does not meet the "research and development-intensive" criteria, the drugs lose their exemption starting the next plan year.
- Application Process: Manufacturers must submit an annual application to the Secretary of Health and Human Services (HHS) before each year starting in 2029. This includes:
- Data on net revenue and R&D spending.
- A certification of accuracy.
- Any additional information requested by HHS.
- Dispute Resolution: HHS must create an appeals process for manufacturers denied the exemption, with decisions finalized before the public announcement of drugs selected for negotiation.
Significant Changes to Existing Law
- Amends Section 1192(d)(2) of the Social Security Act by adding a new subparagraph (D), which introduces the first targeted exemption based on company size, R&D investment, and foreign ownership for Medicare's drug price negotiation program.
- Previously, the program applied broadly to single-source drugs without such carve-outs for small innovators, potentially subjecting all high-cost drugs to negotiation regardless of the manufacturer's scale or investment focus.
- The change applies only to initial price applicability years starting in 2029, leaving earlier years (2026–2028) unaffected.
Potential Impacts
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS) and HHS will need to review applications, verify financial data, and handle appeals, increasing administrative workload and costs. This could strain resources but promote transparency in R&D reporting.
- On Citizens: Medicare beneficiaries (primarily older adults and disabled individuals) might face higher drug costs if exempted drugs are not negotiated down, potentially increasing out-of-pocket expenses or program spending. However, it could lead to more innovative treatments over time by supporting small biotechs.
- On International Relations: Minimal direct impact, but the exclusion of foreign-controlled entities reinforces U.S. policies on national security and supply chain independence in pharmaceuticals.
- Broader Economy: Encourages R&D investment in U.S.-based small biotechs, potentially boosting job creation and innovation in the biotech sector, but at the risk of higher overall healthcare costs if fewer drugs are negotiated.
Main Stakeholders Affected
- Small Biotech Manufacturers: Primary beneficiaries, as the exemption shields their limited product lines from price pressures, allowing reinvestment in R&D.
- Medicare Beneficiaries and Taxpayers: Indirectly affected through potential increases in Medicare drug spending (estimated at billions annually if negotiations are bypassed).
- Larger Pharmaceutical Companies: May face competitive advantages for small firms but could benefit from acquisitions (though with delayed exemptions post-purchase).
- Government Agencies (HHS/CMS): Responsible for implementation, oversight, and enforcement.
- Healthcare Providers and Insurers: Could see varied drug pricing effects, influencing treatment access and costs.
Notable Legal, Constitutional, or Political Implications
- Legal: Builds on the existing Medicare framework without altering core negotiation authority; requires HHS to establish clear processes for applications and disputes to avoid legal challenges over fairness or transparency. The foreign ownership restriction aligns with U.S. trade and security laws but could invite scrutiny if deemed overly restrictive.
- Constitutional: No major issues, as it involves congressional regulation of interstate commerce and spending under Medicare, which has long been upheld.
- Political: Highlights tensions between promoting pharmaceutical innovation (a priority for industry supporters) and controlling drug costs (a key goal for consumer advocates). Could spark debates on equity, as it favors small U.S. biotechs while excluding foreign ones, potentially influencing future healthcare reform bills.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-06-03: Read twice and referred to the Committee on Finance.
- 2025-06-03: Introduced in Senate
Bill Versions
- Small Biotech Innovation Act — issued 2025-06-03 — PDF (6 pages)